Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

Fig. 3

The pooled SMD of monthly headache days in different doses compared with placebo. The green square indicates the estimated SMD for each RCT. The size of green square indicates the estimated weight of each RCT, and the extending lines indicate the estimated 95% CI of SMD for each RCT. The black diamond indicates the estimated SMD (95% CI) for all patients together. CI, confidence interval; RCT, randomized controlled trial; SMD, standard mean difference

Back to article page